Nicox SA · EURONEXT:ALCOX
Nicox SA — Investor Presentation (April 2024)
23 slides from Nicox SA's investor presentation, Apr 4, 2024

Slide 1: Nicox Corporate Presentation
Nicox Corporate Presentation An international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health April 4, 2024

Slide 2: Forward-Looking statements
Forward-Looking statements This document has been prepared by Nicox SA and may not be reproduced or distributed, in whole or in part. The information contained in this document has not been independently verified and no representation, warranty or undertaking, expressed or implied, is made as to, an

Slide 3: Nicox is focused on the value inflection points expected for 2024-2025
Nicox is focused on the value inflection points expected for 2024-2025 ¥ Appointment of Gavin Spencer as Chief Executive Officer Recent Highlights v¥ Anew validation of NCX 470 though Kowa partnership v Restructuring of debt agreements with BlackRock v¥ Streamlining costs to prioritize NCX 470 clini

Slide 4: Consistently delivering innovations in ophthalmology
Consistently delivering innovations in ophthalmology ... al partnerships with r 1 ophthalmology gb ophthalmology stage Phase 3 Ravers experience development ad > A potentially differentiated > €4.2m royalty revenue in 2023 > Two FDA approved profile targeting ~$6bn (429% over 2022) products worldwid

Slide 5: Important achievements in 2023 position the company for 2024 milestones
i) a] Oo a gu B < fe} Y 2 Highlights Important achievements in 2023 position the company for several positive milestones in 2024 NCX 470 Phase 3 Denali trial on track (80% randomized and full one-year safety cohort enrolled) All activities ongoing to support the New Drug Application as planned ZERVI

Slide 6: An innovative portfolio led by NCX 470
An innovative portfo Lio Led by NCX 470, a derisked product candidate with global potential Stages of Development 3 Product Candidates Preclinical Phase 1 Phase 2 Phase 3 NDA Marketed = Expected Milestones Denali topline results in H2 2025 NCX 470 | NO-donating bimatoprost eye d Gl | nating Dimatopr

Slide 7: Glaucoma snapshot
Glaucoma snapshot Elevated IOP contributes to irreversible optic nerve damage, Leading to progressive vision Loss damage to the optic nerve head normal reduced aqueous aqueous humor humor outflow outflow \/ ~ \ Vitreous ee ae healthy eye IOP builds up \ vitreous: anterior chamber ens —+ optic nerve

Slide 8: Unmet medical needs for Glaucoma treatment
Unmet medical needs for Glaucoma treatment ¥ 40% of patients do not achieve their target IOP on existing monotherapies' V Tolerability issues with some medications lead to discontinuations, Despite having well established first-line therapies, including the standard-of-care, Latanoprost, patients do

Slide 9: NCX 470 mechanism of action
1 2 1. Same mechanism of action as Nicox’s first commercialized NO-donating product, latanoprostene bunod 2. Bastia et al. J Ocul Pharmacol Ther. 2022, 38: 496-504

Slide 10: Positive NCX 470 Mont Blanc topline results
Positive NCX 470 Mont Blanc topline results’? Phase 3 clinical program intended to support planned U.S. & China NDA submissions Designed to demonstrate safety and efficacy of NCX 470 0.1% vs. Latanoprost 0.005%, defined by IOP reduction from time-matched baseline at pre-established time points lence

Slide 11: Mont Blanc study design and dosage arms
1. This schematic reflects the dosage arms which continued in the trial and do not include the NCX 470 0.065% dose which was only in the adaptive design portion of the trial

Slide 12: IOP reduction versus latanoprost
As published in the landmark EMGT study “…each mmHg of decreased IOP was related to an approximately 10% lowering [of risk of vision loss progression]”1 1. This data reflects the dosage arms which continued in the trial and do not include the NCX 470 0.065% dose which was only in the adaptive design

Slide 13: NCX 470 0.1% vs Latanoprost 0.005% results
NCX 470 0.1%: N = 328 Latanoprost 0.005%: N = 333 • Denotes statistically significant differences vs latanoprost (p<0.049) • Fechtner et al., AJO, published, 2024 - https://doi.org/10.1016/j.ajo.2024.03.002

Slide 14: Statistically significant differences vs latanoprost
• * * * * • • * Denotes statistically significant differences vs latanoprost (p<0.049)

Slide 15: NCX 470 safety and tolerability
• • • • ≤ • • NCX 470 was well • • • 1. This data reflects the dosage arms which continued in the trial and do not include the NCX 470 0.065% dose which was only in the adaptive design portion of the trial.

Slide 16: NCX 470 presentations at key ophthalmology conferences
NCX 470 - Presentations at key ophthalmology conferences OM ERAN + Poster 1: Intraocular Pressure Reduction with NCX 470 versus Latanoprost Across the Spectrum of Baseline Intraocular SOCIETY Pressures + Poster 2: Intraocular Pressure Reduction with NCX 470 versus Latanoprost In Previously Treated V

Slide 17: U.S. glaucoma clinical advisory board with leading experts
U.S. glaucoma clinical advisory board with leading experts DR. ROBERT D. FECHTNER, MD, CHAIRMAN Professor and Chair of the Department of Ophthalmology at SUNY Upstate Medical University, Syracuse, NY DR. SANJAY G. ASRANI, MD Professor of Ophthalmology at Duke University in Durham, North Carolina, an

Slide 18: Value proposition of NCX 470
< fe} S 2 Value proposition of NCX 470 Novel molecule with competitive positive impact on lowering intraocular pressure (IOP), the leading cause of glaucoma Positive pivotal Phase 3 topline results from the Mont Blanc trial!23 First non-combination product to demonstrate statistical non-inferiority

Slide 19: NCX 470, VYZULTA, ZERVIATE
NCX 470 ✔ ✔ VYZULTA ✔ ZERVIATE ✔

Slide 20: A refocused global leadership team
A refocused global leadership team Gavin Spencer Sandrine Gestin Doug Hubatsch Chief Executive Officer VP, Finance EVP, Chief Scientific Officer tb NOVARTIS tb NOVARTIS t+) soors nmin Alcon INTERNATIONAL Jean-Francois Labbe Michele Garufi Les Kaplan Chairman of the Board Director Director y . [ NY [

Slide 21: Financial highlights
Financial highlights Cash balance expected to support current operations through November 2024 Estimated Financial Position and Ownership Cash, Cash Equivalents as at 31 December 2023 €14.9 million (including the upfront payment from Kowa in February) Long term debt? as at 28 February 2024 €18.2 mil

Slide 22: Investment highlights
Investment highlights proven track record in clinical development and business develo * Two product approvals in the U.S., one pending in China * Business development deals in the U.S., Japan, China, and globally with Tier 1 companies vy NCX 470, a derisked, late-stage development program * Positive

Slide 23: Nicox contact details
nicox visible science B Nicox S.A. Sundesk Sophia Antipolis Emerald Square Batiment C rue Evariste Galois, 06410 Biot, France T: +33 (0)4 97 24 53 OO Nicox Research Institute S.r.L. | Via Ariosto 21 20091 Bresso Milano, Italy T: +39 O2 61 03 61 F: +39 O2 61 03 64 30 Nicox OphthalLmics, Inc. 4819 Emp
Source: Internet Archive copy of nicox.com
More decks from Nicox SA
Investor Presentation (October 2026)26 slides · Oct 30, 2026
Investor Presentation (September 2026)28 slides · Sep 11, 2026
Investor Presentation (April 2026)25 slides · Apr 30, 2026
Investor Presentation (February 2026)25 slides · Feb 24, 2026
Investor Presentation (January 2026)25 slides · Jan 5, 2026
Investor Presentation (January 2026)25 slides · Jan 5, 2026